Clinical Pearls of Depression

Edit Answers
12345678910111213141516171819202122
Across
  1. 6. Adjunctive treatment to reconsider when weight gain or metabolic adverse effects are major concerns
  2. 8. Depression with severe insomnia and poor appetite when weight gain is acceptable
  3. 9. Adjunctive treatment with partial dopamine agonism when akathisia and weight gain can be monitored
  4. 10. Rapid-acting adjunctive option when a rapid antidepressant effect is an important consideration
  5. 11. Intranasal rapid-acting adjunctive option requiring administration in a monitored setting
  6. 12. Adjunctive treatment when minimizing metabolic effects is important while monitoring for akathisia
  7. 14. Treatment to consider when severe depression requires a particularly rapid and robust response
  8. 15. Depression when minimizing sexual dysfunction and weight gain is a priority, provided seizure risk is not a concern
  9. 18. Adjunctive treatment when slow titration and monitoring for serious rash are feasible
  10. 19. Depression when anticholinergic burden, weight gain, or sexual adverse effects are undesirable
  11. 20. Adjunctive treatment when its efficacy must be weighed against sedation and metabolic adverse effects
  12. 22. Depression when blood pressure is adequately controlled and an SNRI is otherwise appropriate
Down
  1. 1. SSRI associated with dose-dependent QTc prolongation, making it less attractive when significant QT risk is present
  2. 2. Depression in a patient taking numerous medications where its extensive CYP inhibition may complicate drug interactions
  3. 3. Depression in a patient particularly concerned about antidepressant discontinuation symptoms
  4. 4. Depression where cognitive symptoms and sexual adverse effects are important treatment considerations
  5. 5. Depression requiring an SSRI when minimizing clinically important CYP drug interactions is a priority
  6. 7. Depression where circadian symptoms are prominent and regular liver-function monitoring is feasible
  7. 13. Adjunctive treatment when ongoing renal, thyroid, and serum-level monitoring is feasible
  8. 16. Adjunctive treatment to reconsider when hyperprolactinemia or sexual adverse effects are already problematic
  9. 17. Depression accompanied by diabetic neuropathic pain
  10. 21. Depression with prominent insomnia when sedation and orthostatic hypotension are acceptable